KMT2A and breast cancer: To determine whether combined PI3K/MLL1 inhibition overcomes PI3K inhibitor–induced cytostasis, we treated PI3K-activated, HR+ breast cancer cells with the PI3K inhibitor alpelisib, the MLL1 inhibitor MI-503, or the combination, and evaluated cellular viability.